A combination of patient-reported subjective cognitive impairment and measurable clinical symptoms, such as amyloid-beta accumulation in the cerebrospinal fluid, may help in the early diagnosis of Alzheimer's disease.
Proteins belonging to the TAM family receptors may be a new biomarker for Alzheimer's disease. The elevated inflammatory markers are conspicuous, even before the onset of dementia.
Some viral infections could increase intercellular spreading of protein aggregates associated with neurodegenerative disorders, increasing the risk for developing Alzheimer's, Parkinson's, and other neurodegenerative diseases.
In the early stages of neurodegenerative diseases, microglia consume glucose to a greater extent than previously believed. The findings may serve as a new biomarker for a range of neurodegenerative disorders.
A newly designed synthetic compound could act as a prototype for a novel class of drugs to treat neurological damage.
In mouse models of Alzheimer's disease, active neurons still encode memory, and a group of active neurons encodes novel environmental information. The signal of the novelty containing neurons causes a superimposition disturbing the signal of memory encoding neurons.